8-K: Danimer Scientific Announces Preliminary 2023 Results, Expects Profitability in Early 2025

Danimer Scientific reported preliminary fourth quarter and full year 2023 results, highlighting an 11% year-over-year increase in PHA revenue for the fourth quarter and projecting to be Adjusted EBITDA positive in early 2025.

Summary

• Danimer Scientific released preliminary financial results for the fourth quarter and full year of 2023.
• The company's fourth-quarter revenue was $10.9 million, down from $15.3 million in the same period of 2022, primarily due to a $4.9 million decrease in PLA revenue related to the conflict in Ukraine.
• However, PHA revenue increased by $0.9 million in the fourth quarter compared to the previous year.
• Full-year 2023 revenue totaled $46.7 million, a decrease from $53.2 million in 2022, with a $6.1 million reduction in PLA revenue due to the Ukraine conflict.
• PHA revenue for the full year increased by $1.8 million compared to 2022.
• Adjusted EBITDA for the fourth quarter was $(10.7) million, compared to $(8.6) million in the fourth quarter of 2022.
• The full-year Adjusted EBITDA was $(39.0) million, an improvement from $(45.0) million in 2022, mainly due to expense control measures.
• The company expects a 60% year-over-year increase in PHA sales in the first quarter of 2024.
• Danimer anticipates its Kentucky facility to become Adjusted EBITDA positive when it reaches just over 30% capacity utilization.
• The company as a whole is expected to become Adjusted EBITDA positive when the Kentucky facility reaches 70-80% capacity utilization, near the start of 2025.
• The company had $59.2 million in unrestricted cash and cash equivalents at the end of 2023, with an additional $14.3 million in restricted cash.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the projected growth in PHA sales and the expectation of achieving profitability in early 2025. However, the negative Adjusted EBITDA and revenue decline in 2023 temper the overall positive outlook.

Positives

• PHA revenue showed growth in the fourth quarter of 2023, increasing by 11% year-over-year.
• The company expects a significant 60% increase in PHA sales in the first quarter of 2024.
• Danimer is projecting to achieve Adjusted EBITDA profitability in early 2025.
• The company has secured a 20-million-pound cutlery award, which is expected to drive future growth.
• The company's Adjusted EBITDA improved year-over-year, indicating progress in expense control.

Negatives

• Total revenue decreased in both the fourth quarter and full year of 2023 compared to 2022.
• The conflict in Ukraine significantly impacted PLA revenue, causing a $4.9 million decrease in the fourth quarter and a $6.1 million decrease for the full year.
• The company reported a negative Adjusted EBITDA for both the fourth quarter and full year of 2023.
• Service revenue decreased in 2023 compared to 2022 as long-term R&D projects were completed.

Risks

• The company's financial results are preliminary and unaudited, and final results may differ.
• The ongoing conflict in Ukraine continues to impact the company's revenue.
• The company's ability to achieve profitability is dependent on reaching specific capacity utilization rates at its Kentucky facility.
• The company faces risks related to consumer demand, economic conditions, and global market volatility.
• There are risks associated with the company's ability to expand production facilities and meet customer demand.

Future Outlook

The company expects a 60% year-over-year increase in PHA sales in the first quarter of 2024 and anticipates becoming Adjusted EBITDA positive in early 2025. The 20-million-pound cutlery award is expected to reach full run rate in the second quarter of 2025.

Management Comments

• Stephen E. Croskrey, Chairman and CEO, stated that they are pleased with the continued year-over-year PHA revenue growth in the fourth quarter.
• Mr. Croskrey expects growth to accelerate in 2024 with increased volumes from existing and new customers.
• Mr. Croskrey confirmed the projected profitability timeline for the Kentucky operation and the company as a whole.

Industry Context

The announcement reflects the growing interest in sustainable bioplastics, with Danimer positioning itself as a key player in the development and production of biodegradable materials. The company's focus on PHA aligns with the increasing demand for eco-friendly alternatives to traditional plastics.

Comparison to Industry Standards

• Danimer's focus on PHA is a differentiator in the bioplastics market, where many companies focus on PLA or other bio-based polymers.
• While specific financial comparisons to direct competitors are not provided, the company's projected profitability timeline and capacity utilization targets are key metrics to watch against industry benchmarks.
• Companies like NatureWorks (PLA) and Novamont (bioplastics) are key competitors in the broader bioplastics market, but Danimer's focus on PHA and its specific applications sets it apart.
• The 60% projected increase in PHA sales in Q1 2024 is a significant growth target compared to the more modest growth rates of some other bioplastics companies.

Stakeholder Impact

• Shareholders may be encouraged by the projected growth and profitability timeline, but concerned about the current losses and revenue decline.
• Employees may be impacted by the company's efforts to control expenses.
• Customers may benefit from the increased availability of PHA-based products.
• Suppliers may see increased demand for raw materials as the company scales up production.

Next Steps

• The company will host a webcast and conference call on March 28, 2024, to discuss the results.
• The company will focus on scaling up production to meet the demand from the 20-million-pound cutlery award.
• The company will work towards achieving Adjusted EBITDA profitability in early 2025.

Key Dates

Keywords

PHA, bioplastics, Adjusted EBITDA, revenue, biodegradable, profitability, Danimer Scientific, financial results, capacity utilization, Kentucky facility